Adaptive Biotechnologies is a commercial-stage immune-driven medicine company developing an immunosequencing platform that combines proprietary chemistry, computational biology, and machine learning to decode the adaptive immune system. The company's flagship diagnostic product, clonoSEQ, detects and monitors minimal residual disease (MRD) in multiple myeloma, B-cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia. The immunoSEQ platform serves academic researchers and pharmaceutical companies developing diagnostics and therapeutics.
Adaptive Biotechnologies is publicly traded
IPO'd on June 27, 2019
This company is no longer available on our private secondary market. Shares can be traded publicly under ADPT.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2009
Employees
501–1,000
Total Funding
$245M
4 rounds
Total raised $245M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series F-2 / late-stage
Date
January 22, 2018
Amount
Not disclosed
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| January 22, 2018 | Series F-2 / late-stage | Not disclosed | — | Not disclosed |
| 2017 | Series F-1 | $50M | — | Microsoft |
| 2015 | Series F | $195M | — | Matrix Capital |
Chad Robins
CEO, Co-Founder & Chairman
Harlan Robins
Chief Scientific Officer & Co-Founder
Kyle Piskel
Chief Financial Officer
Sharon Benzeno
Chief Commercial Officer, Immune Medicine
Susan Bobulsky
Chief Commercial Officer, MRD
Francis Lo
Chief People Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Omniscope
Competitor in immune sequencing and diagnostic services
Strata Oncology
Cancer genomics and precision oncology competitor
ImmuneWatch
Immune monitoring and diagnostics competitor
Illumina
Sequencing technology provider; competes in genomics and immune profiling
Takara Bio
T-cell receptor (TCR) sequencing competitor; ranked high in benchmarking studies
iRepertoire
TCR and immune repertoire sequencing competitor
Yes, Adaptive Biotechnologies is publicly traded under the ticker symbol ADPT on the NASDAQ. The company went public in June 27, 2019.
Adaptive Biotechnologies trades under the ticker symbol ADPT on the NASDAQ. It began trading in June 27, 2019.
Adaptive Biotechnologies (ADPT on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ADPT to place an order.
Adaptive Biotechnologies went public in June 27, 2019 via ipo. Adaptive Biotechnologies completed its initial public offering on June 27, 2019, raising $300 million at $20 per share. The stock more than doubled on its first trading day, closing at $40.30. The company trades on NASDAQ under ticker ADPT and is one of the largest immunosequencing companies by market capitalization.
Adaptive Biotechnologies raised $245M across 4 disclosed funding rounds prior to its public listing.
Adaptive Biotechnologies was co-founded by Chad Robins, and Harlan Robins in 2009.
Adaptive Biotechnologies is headquartered in Seattle, WA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.